KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Cash (2016 - 2025)

Pacira BioSciences has reported Change in Cash over the past 16 years, most recently at $11.0 million for Q4 2025.

  • Quarterly results put Change in Cash at $11.0 million for Q4 2025, down 64.44% from a year ago — trailing twelve months through Dec 2025 was -$118.2 million (down 195.75% YoY), and the annual figure for FY2025 was -$118.2 million, down 195.75%.
  • Change in Cash for Q4 2025 was $11.0 million at Pacira BioSciences, up from -$152.9 million in the prior quarter.
  • Over the last five years, Change in Cash for PCRX hit a ceiling of $451.5 million in Q4 2021 and a floor of -$358.8 million in Q1 2022.
  • Median Change in Cash over the past 5 years was $11.6 million (2023), compared with a mean of $2.9 million.
  • Biggest five-year swings in Change in Cash: soared 1885.67% in 2021 and later tumbled 13952.85% in 2025.
  • Pacira BioSciences' Change in Cash stood at $451.5 million in 2021, then tumbled by 101.17% to -$5.3 million in 2022, then soared by 1125.15% to $54.2 million in 2023, then plummeted by 43.13% to $30.8 million in 2024, then tumbled by 64.44% to $11.0 million in 2025.
  • The last three reported values for Change in Cash were $11.0 million (Q4 2025), -$152.9 million (Q3 2025), and $16.9 million (Q2 2025) per Business Quant data.